Pierre B.
- Country
- France
- Department
- Medical Oncology - Early Phase Unit
Research Overview
- Phase I Study of OT-A201 in Patients with Relapsed/Refractory Hematological Malignancies or Advanced/Metastatic Solid Tumors
- Phase 1 Evaluation of JNJ-88549968, a T-cell Redirecting Antibody, in Patients with CALR-mutated Myeloproliferative Neoplasms
- Open-label dose-finding and dose-expansion study to evaluate the safety, expansion, persistence, and clinical activity of UCART20x22 in subjects with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL)
Data & Insights
Has run more than one trial at 74 of 176 partner sites.
Specializations
Hematologic Malignancies
The investigator specializes in treating chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), with particular emphasis on novel therapeutic approaches for these blood cancers.
- Previously untreated CLL/SLL
- Relapsed/refractory CLL
- Richter's Syndrome
Their research extends to elderly patients over 70 years with these conditions, addressing specific treatment needs of this population.
Therapeutic Innovations
The investigator focuses on evaluating novel treatment combinations including targeted therapies and monoclonal antibodies for blood cancers.
- BTK inhibitor combinations
- Venetoclax-based regimens
- Novel antibody therapies
Their work includes investigating innovative dosing schedules and treatment duration optimization strategies.
Treatment Optimization
The investigator explores MRD-guided treatment approaches and fixed-duration therapies to enhance patient outcomes.
- Treatment duration optimization
- Novel dosing schedules
- Combination therapy assessment
Their research includes evaluation of treatment interruption strategies and safety monitoring in various therapeutic approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.